List of Excipients in Branded Drug SILENOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Currax Pharmaceuticals LLC	SILENOR	doxepin hydrochloride	42847-103	CELLULOSE, MICROCRYSTALLINE
Currax Pharmaceuticals LLC	SILENOR	doxepin hydrochloride	42847-103	FD&C BLUE NO. 1
Currax Pharmaceuticals LLC	SILENOR	doxepin hydrochloride	42847-103	MAGNESIUM STEARATE
Currax Pharmaceuticals LLC	SILENOR	doxepin hydrochloride	42847-103	SILICON DIOXIDE

Silenor Excipient Strategy and Commercial Opportunities for Doxepin Tablets

Last updated: August 16, 2026

Silenor is a low-dose doxepin hydrochloride tablet approved for the treatment of insomnia characterized by difficulty with sleep maintenance. Its commercial opportunity is concentrated in generic 3 mg and 6 mg tablets, excipient-optimized products, and differentiated oral delivery systems rather than in new chemical-entity exclusivity. The most practical strategy is a low-cost immediate-release tablet that matches the reference product’s quality attributes while removing avoidable formulation liabilities such as colorants, lactose, or poor dose flexibility.

What is Silenor and which dosage forms are commercially relevant?

Silenor contains doxepin hydrochloride in 3 mg and 6 mg film-coated tablets. The product is administered shortly before bedtime and is indicated for sleep-maintenance insomnia. The low dose distinguishes Silenor from older doxepin products used for depression and anxiety, which were marketed at substantially higher doses.[1]

Attribute	Silenor
Active ingredient	Doxepin hydrochloride
Therapeutic class	Tricyclic compound; insomnia treatment
FDA application	NDA 022036
Approved strengths	3 mg and 6 mg
Dosage form	Immediate-release film-coated tablet
Primary indication	Insomnia characterized by difficulty with sleep maintenance
Sponsor at approval	Somaxon Pharmaceuticals
Current commercial relevance	Reference product for low-dose doxepin generic development
Controlled-substance status	Doxepin is not federally scheduled as a controlled substance

Silenor’s formulation is technically uncomplicated compared with modified-release, peptide, or sterile products. The principal development challenge is the very low drug load. A 3 mg tablet requires consistent blend uniformity, content uniformity, and dose-to-dose control despite the relatively large mass of excipients.

What excipients are used in Silenor tablets?

The FDA prescribing information identifies a conventional immediate-release tablet platform. The listed inactive ingredients include lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, colloidal silicon dioxide, magnesium stearate, and talc. The film coating contains additional coating materials and colorants.[1]

Excipient or excipient class	Likely formulation function	Commercial and technical relevance
Lactose monohydrate	Diluent and compression aid	Low cost and widely available; creates a lactose-free differentiation opportunity
Microcrystalline cellulose	Diluent, dry binder, disintegration support	Standard direct-compression excipient with broad supplier coverage
Pregelatinized starch	Binder and disintegrant	Supports tablet strength and breakup
Crospovidone	Superdisintegrant	Helps achieve rapid disintegration at low drug loading
Colloidal silicon dioxide	Glidant and flow aid	Important for low-dose blend flow and content uniformity
Magnesium stearate	Lubricant	Over-lubrication can slow wetting, disintegration, and dissolution
Talc	Processing aid or coating component	May be removed in a simplified or “clean-label” formulation
Film-coating polymers and colorants	Protection, appearance, identification	Colorant-free and reduced-coating products may offer differentiation

The label is the controlling source for the reference product’s inactive-ingredient composition. Formulation developers should not assume that every excipient in the reference product is necessary for a generic product. An ANDA applicant can use a different qualitative and quantitative excipient system if the product meets applicable pharmaceutical equivalence, bioequivalence, quality, and labeling requirements.

Which excipient strategy is most attractive for a generic Silenor product?

A conventional immediate-release tablet remains the highest-probability strategy. The formulation should prioritize:

1. Uniform distribution of doxepin at 3 mg and 6 mg.
2. Robust tablet compression at low drug loading.
3. Rapid and reproducible disintegration.
4. Comparable dissolution across the intended pH range.
5. Low friability and acceptable film-coating performance.
6. Manufacturing flexibility across multiple tablet sizes or strengths.

A practical formulation platform would use microcrystalline cellulose or another direct-compression diluent, a controlled level of crospovidone or equivalent superdisintegrant, colloidal silicon dioxide for flow, and a low level of magnesium stearate. The formulation should avoid excessive lubricant exposure and prolonged blending after lubrication.

Should a generic manufacturer retain lactose?

Lactose is commercially efficient, but removal may create market value. A lactose-free tablet could address patients who avoid lactose because of intolerance, dietary preference, or excipient sensitivity. The business case is strongest if lactose removal does not increase tablet size, manufacturing cost, or dissolution variability.

A lactose-free platform could replace lactose with combinations of microcrystalline cellulose, mannitol, dibasic calcium phosphate, silicified microcrystalline cellulose, or co-processed excipients. Each substitution changes tablet density, compactability, disintegration, and blend segregation risk. A direct substitution without comparative development work would create avoidable quality risk.

Should a generic manufacturer remove colorants?

Colorants are not required for therapeutic performance, but they assist strength identification and reduce medication-selection errors. A colorant-free product could appeal to customers seeking simpler excipient profiles, but it would require alternative differentiation through tablet shape, debossing, packaging, or separate blister presentation.

The commercial tradeoff is clear:

Option	Benefit	Risk
Match colored reference tablets	Familiar appearance and lower switching friction	Retains colorant-related sensitivity and sourcing issues
Use a different color	Strong product identification	May increase medication-error or substitution concerns
Use white tablets with debossing	Simplified excipient profile	Requires stronger packaging and labeling controls
Use color-free film coating	Potential formulation differentiation	May reduce visual product distinction

What formulation patents protect Silenor?

Silenor’s historical exclusivity was associated primarily with low-dose doxepin use in insomnia rather than with a complex excipient platform. The key commercial distinction is between method-of-use protection and formulation protection.

The original Silenor patent estate included patents directed to the use of low-dose doxepin for insomnia. Those rights were separate from the excipient choices disclosed in the commercial tablet. A conventional generic applicant generally does not need to reproduce the reference product’s exact excipient composition.

Protection category	Relevance to Silenor
Active ingredient patents	Not commercially relevant because doxepin is an established active ingredient
Low-dose insomnia method patents	Historically important to launch timing
Specific formulation patents	Relevant only if an unexpired patent claims the selected composition or performance
Manufacturing patents	Could affect process replication, but conventional tablet manufacturing generally permits alternative processes
Trademark rights	Protect “Silenor,” not the active ingredient or generic formulation

The applicant must review the current FDA Orange Book patent listing for NDA 022036 and relevant patent records before filing. The commercial opportunity depends on the absence of blocking unexpired claims, the applicable certification strategy, and whether the proposed label can omit protected methods of use.[2]

When does Silenor lose exclusivity and what is the generic launch risk?

Silenor’s FDA approval occurred in 2010. The product’s regulatory exclusivity period has expired. The principal generic-entry question is therefore patent status, not remaining FDA new-drug exclusivity.

Milestone	Commercial significance
2010 FDA approval	Established the low-dose doxepin insomnia reference product
Expiration of regulatory exclusivity	Removed the principal non-patent barrier to ANDA competition
Expiration of historic low-dose-use patent rights	Opened the market to generic low-dose doxepin, subject to current listings and litigation
Generic approval	Creates price pressure and accelerates payer substitution
Multiple generic entrants	Compresses margins and shifts competition toward manufacturing cost and supply reliability

The strongest generic launch scenario is a paragraph IV or post-patent ANDA strategy using a standard immediate-release tablet. A 505(b)(2) application could support a new dosage form, excipient profile, or delivery technology, but it would require a stronger clinical or pharmacokinetic rationale than a conventional ANDA.

Which companies are challenging Silenor, and what is the litigation status?

Low-dose doxepin is exposed to generic competition from manufacturers capable of producing 3 mg and 6 mg immediate-release tablets. The relevant competitive set includes large generic companies, specialty-generic manufacturers, and contract development and manufacturing organizations with low-dose oral-solid-dose capabilities.

Publicly available FDA sources identify the reference NDA and approved product information, but commercial litigation and settlement details must be evaluated against current court dockets and Orange Book records. Historic patent litigation relating to low-dose doxepin should not be treated as a current barrier without confirming whether the asserted patents remain enforceable and listed.

For business planning, the key litigation questions are:

• Whether an ANDA applicant has filed a paragraph IV certification.
• Whether the NDA holder filed an infringement action within the statutory period.
• Whether a 30-month stay was triggered.
• Whether the parties entered a launch settlement.
• Whether the settlement includes a licensed-entry date, authorized generic arrangement, or supply agreement.
• Whether any settlement restricts formulation changes or alternative dosage forms.

A patent settlement can alter practical entry timing even after the underlying patent has limited remaining life. It can also create an opportunity for a second-wave entrant using a non-infringing excipient system or different dosage form.

What commercial opportunities exist for Silenor excipient innovation?

1. Lactose-free generic tablets

A lactose-free 3 mg and 6 mg product is the most straightforward excipient-led opportunity. The target market includes patients with lactose intolerance and pharmacies or health systems that prefer simplified inactive-ingredient profiles.

The product must preserve:

• Assay and content uniformity.
• Comparable dissolution.
• Adequate tablet hardness.
• Low friability.
• Acceptable stability.
• Scalable compression performance.

2. Colorant-free tablets

A colorant-free product can reduce dependence on dye suppliers and address excipient-sensitivity concerns. The opportunity is more commercial than therapeutic. Packaging, debossing, and tablet geometry would need to distinguish the two strengths.

3. Smaller tablets and dose-flexible presentations

Doxepin’s low dose creates an opportunity for compact tablets, scored tablets, or unit-dose blister packaging. A scored 6 mg tablet could provide practical dose flexibility, but score performance, content uniformity of split portions, and labeling would require regulatory support.

4. Orally disintegrating tablets

An orally disintegrating tablet could target patients who have difficulty swallowing or who want bedtime administration without water. This would likely require a 505(b)(2) strategy unless the product qualifies under an applicable ANDA pathway.

Key development constraints include:

• Taste masking for doxepin.
• Mechanical strength during packaging and distribution.
• Moisture protection.
• Rapid disintegration.
• Acceptable mouthfeel.
• Dose uniformity at very low drug loading.

5. Sprinkle or multiparticulate products

A sprinkle product could serve patients with swallowing limitations. The product would need data showing that the drug can be administered with the proposed food vehicle without unacceptable changes in exposure or dissolution. Multiparticulate systems increase manufacturing and packaging complexity, so the commercial opportunity is narrower than for a standard tablet.

6. Unit-dose blister packaging

Packaging is an underused differentiation route. Unit-dose blisters can support adherence, reduce tablet mix-ups between 3 mg and 6 mg strengths, and fit institutional or travel use. The value is greater for specialty pharmacy, hospital discharge, and direct-to-consumer channels than for commodity retail generics.

How strong is the Silenor patent estate?

The patent estate is materially weaker than the estate of a recently launched branded drug because doxepin is old, the low-dose insomnia product was approved in 2010, and regulatory exclusivity has expired. Any remaining commercial protection would depend on specific unexpired method, formulation, or manufacturing claims.

Strength factor	Assessment
New chemical entity protection	None of practical relevance
Regulatory exclusivity	Expired
Historic low-dose insomnia patents	Important historically; current enforceability must be assessed by patent
Complex formulation barrier	Limited
Manufacturing barrier	Limited for standard tablets
Excipient substitution opportunity	High
Biosimilar barrier	Not applicable
Generic price pressure	High

The formulation estate is unlikely to prevent a technically competent manufacturer from developing a non-identical excipient composition. The more meaningful barriers are regulatory execution, low-dose content uniformity, commercial scale, supply continuity, and access to pharmacy benefit channels.

What is the FDA regulatory status and Orange Book position?

FDA approved Silenor under NDA 022036 for sleep-maintenance insomnia.[1] FDA’s Orange Book identifies approved drug products, therapeutic-equivalence information, and applicable listed patents or exclusivity data.[2]

For a conventional generic tablet, the expected pathway is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. An applicant using a materially different delivery system, a new route, or a new clinical claim may require a 505(b)(2) application instead.[3]

The regulatory pathway affects excipient strategy:

Product concept	Likely pathway
Immediate-release 3 mg and 6 mg tablets with different excipients	ANDA, subject to FDA requirements
Lactose-free immediate-release tablet	Usually ANDA if equivalence requirements are met
Colorant-free tablet	Usually ANDA if otherwise equivalent
Orally disintegrating tablet	Potentially 505(b)(2), depending on product design and FDA determination
Sprinkle granules or novel multiparticulates	Potentially 505(b)(2)
New insomnia indication or materially different dosing claim	505(b)(2) or supplemental regulatory strategy

What revenue exposure and competitive dynamics affect Silenor?

The revenue pool is exposed to rapid generic substitution because the product is a small-molecule oral tablet with expired regulatory exclusivity. Brand economics depend on residual prescriber loyalty, payer positioning, supply reliability, and the ability to support a differentiated low-dose insomnia profile.

Generic manufacturers can compete on:

• Manufacturing cost per tablet.
• Reliable supply of low-dose tablets.
• Wholesaler and pharmacy contracting.
• Availability of both strengths.
• Free-from positioning, such as lactose-free or colorant-free formulations.
• Blister or unit-dose packaging.
• Authorized-generic or licensed distribution arrangements.

A manufacturer should avoid overinvesting in a costly delivery platform unless it can demonstrate a clear patient, payer, or channel advantage. The best risk-adjusted opportunity is a scalable immediate-release platform with at least two strength presentations and a differentiated excipient profile.

What geographic coverage and manufacturing barriers apply?

U.S. entry is governed by FDA approval, Orange Book status, and applicable patent certifications. European and other-market opportunities require separate review because doxepin approvals, insomnia indications, reference products, and patent positions vary by jurisdiction.

Manufacturing barriers are modest but real. The critical operations are low-dose dispensing, blending, lubrication, compression, coating, and stability control. A manufacturer should validate:

• Drug distribution throughout the blend.
• Segregation during transfer and hopper residence.
• Tablet weight and content uniformity.
• Lubrication sensitivity.
• Coating weight gain and color consistency.
• Moisture and photostability.
• Stability in commercial packaging.

Contract manufacturers with validated low-dose oral-solid-dose processes can enter without building specialized sterile or biologic infrastructure. That lowers capital requirements and increases the likelihood of multiple generic entrants.

Key Takeaways

• Silenor is a 3 mg and 6 mg immediate-release doxepin hydrochloride tablet for sleep-maintenance insomnia.
• The reference formulation uses conventional excipients, including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, crospovidone, colloidal silicon dioxide, magnesium stearate, and coating materials.
• The strongest excipient-led generic opportunity is a lactose-free, colorant-free, low-cost tablet with reliable content uniformity.
• Orally disintegrating and sprinkle products offer greater differentiation but may require a 505(b)(2) strategy and additional development work.
• Regulatory exclusivity has expired, and the primary entry analysis is current patent listing, certification, litigation, and settlement status.
• Biosimilar risk does not apply because doxepin is a synthetic small molecule.
• Manufacturing complexity is moderate, while commercial pressure is likely to be high once multiple generic suppliers enter.
• A standard immediate-release tablet with a differentiated excipient profile offers the best risk-adjusted commercial path.

FAQs

Can a generic Silenor tablet use different excipients from the reference product?

Yes. A generic applicant generally may use a different excipient composition if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, stability, and labeling.

Is lactose-free doxepin commercially differentiated?

Yes, but the differentiation is primarily patient and channel oriented. Lactose removal can support pharmacy, health-system, and consumer positioning without changing the active ingredient or dosage form.

Does Silenor have biosimilar competition?

No. Doxepin is a synthetic small molecule. Competition is based on generic-drug pathways, not biosimilar approval pathways.

Could an orally disintegrating doxepin product obtain market exclusivity?

Potentially. A novel dosage form may support formulation or regulatory exclusivity, but the scope and duration would depend on the approved pathway, patent claims, clinical data, and FDA determinations.

What is the main technical risk in developing 3 mg doxepin tablets?

The principal risk is low-dose content uniformity. Blend segregation, inadequate sampling, over-lubrication, and inconsistent compression can affect assay, dissolution, and dose delivery.

References

1. U.S. Food and Drug Administration. (2010). Silenor (doxepin hydrochloride) tablets, prescribing information. NDA 022036.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA guidance for industry.

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/